DOSAGE

Smart overview of the Invention

Overview: The patent application discusses a novel approach involving antibodies or binding fragments that target citrulline-containing epitopes. These are used to treat or prevent diseases linked to the release of extracellular traps from cells, specifically Neutrophil Extracellular Trap (NET) and Eosinophil Extracellular Trap (EET) related pathologies. The application emphasizes the importance of administering these antibodies at specific dosages to achieve therapeutic effects.

Targeted Pathologies: NET-associated pathologies cover a wide range of diseases, including systemic lupus erythematosus, rheumatoid arthritis, psoriasis, Alzheimer's, and various respiratory and cardiovascular conditions. EET-associated pathologies involve eosinophilic diseases affecting skin, respiratory, and gastrointestinal systems, as well as allergic diseases and infections. The application highlights the potential of antibodies to mitigate these conditions by interfering with the pathological roles of NETs and EETs.

Mechanism of Action: The antibodies are designed to bind specifically to citrullinated epitopes on deiminated human histone 2A and histone 4. By targeting these structures, the antibodies can inhibit the formation of extracellular traps, thereby reducing inflammation and associated tissue damage. This approach addresses the underlying inflammatory processes that contribute to a variety of chronic and acute diseases.

Dosage and Administration: The patent specifies an effective dosage range for the antibodies, from 0.01 mg/kg to 0.6 mg/kg. This dosage is critical for achieving the desired therapeutic outcomes, such as modulating cytokine levels and reducing inflammatory markers like calprotectin and TNF-alpha. The precise dosage ensures optimal efficacy while minimizing potential side effects.

Implications for Treatment: This innovative treatment strategy offers a promising avenue for managing diseases where extracellular traps play a significant role. By optimizing antibody dosages, the approach not only targets disease mechanisms more effectively but also opens up possibilities for treating conditions previously difficult to manage. The application underscores the potential for these antibodies to improve patient outcomes across a broad spectrum of inflammatory and autoimmune disorders.